알라우노스 테라퓨틱스TCRT 주가

[4] 내부자 거래 — 4

Alaunos Therapeutics Reports Preclinical Results For ALN1003 Showing Weight Loss, Improved Insulin Sensitivity, And Better Liver Health In Obese Mouse Studies

ALN1003 demonstrated consistent, favorable effects across key drivers of metabolic disease, including reductions in body weight and fat mass, improved insulin sensitivity, enhanced adipose function, and improved liver

♻️ 재탕[8-K] 중대 사건 — 8-K

Alaunos reports preclinical ALN1003 data showing effects on insulin-resistance-related biomarkers and liver histology in diet-induced obesity models

Alaunos Therapeutics Inc: Alaunos reports preclinical ALN1003 data showing effects on insulin-resistance-related biomarkers and liver histology in diet-induced Obesity models Alaunos...

Alaunos Therapeutics Issues Updated Preclinical Data From Non-GLP Diet-Induced Obesity Mouse Studies Evaluating ALN1003, Investigational Oral Metabolic Therapeutic Candidate

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) today announced updated preclinical data from non-GLP diet-induced obesity (DIO) mouse studies evaluating ALN1003, the Company's investigational oral metabolic therapeutic

[8-K] 중대 사건 — 8-K

Ziopharm: Q1 Earnings Snapshot

FORT LAUDERDALE, Fla. — FORT LAUDERDALE, Fla. — Alaunos Therapeutics, Inc. on Friday reported a loss of $1 million in its first quarter. The Fort Lauderdale, Florida-based company said it had...

[10-Q] 분기 실적 — 10-Q

[4] 내부자 거래 — 4

[4] 내부자 거래 — 4